| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Fasoracetam targets metabotropic glutamate receptors (mGluR), specifically modulating mGluR II/III activity. It acts as an activator of these receptors. By modulating glutamatergic signaling, Fasoracetam influences cognitive function, memory, and focus. The compound also influences cholinergic signaling.
|
|---|---|
| ln Vitro |
In vitro, Fasoracetam modulates mGluR II/III activity in mouse neurons. It acts as an activator of metabotropic glutamate receptors. The compound enhances cognitive function-related signaling pathways in neuronal cultures. Specific IC50 or EC50 values for receptor activation are not extensively documented in publicly available literature.
|
| ln Vivo |
In vivo, Fasoracetam has been studied in animal models of cognitive impairment and ADHD. It enhances cognitive function, memory, and focus. The compound has shown potential in clinical studies for treating cognitive deficits and certain subtypes of ADHD. However, it failed to show sufficient efficacy in clinical trials for vascular dementia.
|
| Enzyme Assay |
The in vitro receptor binding assay for Fasoracetam involves measuring its affinity for metabotropic glutamate receptors (mGluR). Radiolabeled ligand binding assays are performed using membrane preparations from cells expressing mGluR subtypes. Varying concentrations of Fasoracetam are incubated with the receptor preparation, and binding affinity (IC50 or Ki) is determined. The compound modulates mGluR II/III activity in mouse neurons.
|
| Cell Assay |
In vitro cellular assays for Fasoracetam typically involve treating cultured neuronal cells (e.g., mouse primary neurons) with varying concentrations of the compound. mGluR activation is assessed by measuring downstream signaling events such as intracellular calcium mobilization or cAMP levels using fluorescent indicators or ELISA. Neuronal survival and synaptic plasticity markers may also be evaluated.
|
| Animal Protocol |
In vivo animal experiments for Fasoracetam typically use rodent models of cognitive impairment or ADHD. The compound is administered orally or intraperitoneally at various doses. Cognitive function is assessed using behavioral tests such as the Morris water maze, novel object recognition, or passive avoidance tests. Locomotor activity and anxiety-like behavior may also be evaluated. Brain levels of neurotransmitters and mGluR signaling markers are measured post-mortem.
|
| ADME/Pharmacokinetics |
Fasoracetam is typically administered orally and has shown potential in clinical studies. The compound has a molecular weight of 196.25. As a small molecule racetam derivative, it is expected to have good oral bioavailability and blood-brain barrier penetration. Specific PK parameters (e.g., half-life, Cmax, AUC) are not extensively documented in publicly available literature but would be available from clinical trial data.
|
| Toxicity/Toxicokinetics |
Toxicological data for Fasoracetam are limited in publicly available sources. The compound has been evaluated in clinical trials for vascular dementia and ADHD, suggesting a manageable safety profile. Common adverse effects associated with racetam compounds may include headache, nausea, and gastrointestinal disturbances. Complete toxicology data would be available from the compound's clinical development program.
|
| References | |
| Additional Infomation |
Fasoracetam is an amino acid amide. Fasoracetam is being investigated in the clinical trial NCT03609619 (Part B: AEVI-001: Efficacy and safety of Fasoracetam in children and adolescents with ADHD without the Mglur mutation).
Fasoracetam (CAS#: 110958-19-5) is a racetam family nootropic and metabotropic glutamate receptor activator. It has been investigated for ADHD, Alzheimer's disease, and vascular dementia. The compound failed to show sufficient efficacy in clinical trials for vascular dementia but continues to be studied for ADHD. Fasoracetam is not approved for clinical use and remains an investigational compound. |
| Molecular Formula |
C10H16N2O2
|
|---|---|
| Molecular Weight |
196.24624
|
| Exact Mass |
196.121
|
| CAS # |
110958-19-5
|
| Related CAS # |
1618109-51-5 (tartrate);2055646-53-0 (hydrate);110958-19-5;
|
| PubChem CID |
198695
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
456.8±38.0 °C at 760 mmHg
|
| Flash Point |
230.1±26.8 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.528
|
| LogP |
-1.37
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
14
|
| Complexity |
247
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1CCN(CC1)C(=O)[C@H]2CCC(=O)N2
|
| InChi Key |
GOWRRBABHQUJMX-MRVPVSSYSA-N
|
| InChi Code |
InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1
|
| Chemical Name |
(5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~1273.89 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (10.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (10.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (10.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0955 mL | 25.4777 mL | 50.9554 mL | |
| 5 mM | 1.0191 mL | 5.0955 mL | 10.1911 mL | |
| 10 mM | 0.5096 mL | 2.5478 mL | 5.0955 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
